Antithrombotic therapy management in patients with inherited bleeding disorders and coronary artery disease: A single-centre experience

Haemophilia. 2020 Mar;26(2):e34-e37. doi: 10.1111/hae.13904. Epub 2019 Dec 17.

Authors

Marie-Léa Piel-Julian¹, Marie-Françoise Thiercelin-Legrand^{1

2}, Guillaume Moulis^{1

3}, Sophie Voisin⁴, Ségolène Claeyssens², Laurent Sailler^{1

3}

Affiliations

¹ Service de Médecine Interne, salle Le Tallec, Centre Hospitalier Universitaire de Toulouse-Purpan, Toulouse, France.
² Centre régional d'hémophilie, Centre Hospitalier Universitaire de Toulouse-Purpan, Toulouse, France.
³ Centre d'investigation clinique 1436, axe pharmacoépidémiologie, Centre Hospitalier Universitaire de Toulouse-Purpan, Toulouse, France.
⁴ Laboratoire d'hématologie, Centre Hospitalier Universitaire de Toulouse-Purpan, Toulouse, France.

PMID: 31846115
DOI: 10.1111/hae.13904

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Blood Coagulation Disorders, Inherited / complications
Blood Coagulation Disorders, Inherited / drug therapy*
Coronary Artery Disease / complications
Coronary Artery Disease / therapy*
Female
Fibrinolytic Agents / adverse effects
Fibrinolytic Agents / therapeutic use*
France / epidemiology
Hemophilia A / complications
Hemophilia A / drug therapy
Hemophilia B / complications
Hemophilia B / drug therapy
Hemorrhage / epidemiology
Hemorrhage / etiology
Hemorrhage / prevention & control
Humans
Male
Middle Aged
Myocardial Ischemia / complications
Myocardial Ischemia / physiopathology
Myocardial Ischemia / therapy
Platelet Aggregation Inhibitors / adverse effects
Platelet Aggregation Inhibitors / therapeutic use*
Retrospective Studies
Safety
Treatment Outcome
von Willebrand Diseases / complications
von Willebrand Diseases / drug therapy

Substances

Fibrinolytic Agents
Platelet Aggregation Inhibitors